Scientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation..

Marta Pascual-Gilabert 1, Ruben Artero 2,3, Arturo López-Castel 2,3, (2023). The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discovery Today, 28(3), 103489.
- https://doi.org/10.1016/j.drudis.2023.103489
- https://www.sciencedirect.com/science/article/pii/S1359644623000053

MyoDM, a breakthrough in the treatment of Steinert's Myotonic Dystrophy. Research and innovation at the service of your well-being.

¿Do you have any questions
or need more information?

Fill out the form and our team will respond as soon as possible.

Related news.

Doctoral thesis

Highest qualification awarded by the Thesis Committee: Dr. Rafael Mañez Mendiluce**, Dr. Carmen Escolano Mirón***, Arturo López Castel****

Scientific article compiling the most recent drug development projects currently in the preclinical and clinical phases

View report

Myogem’s MyoDM clinical study successfully completes patient recruitment. Post on LinkedIn

At the end of February 2021, the patient recruitment phase of the clinical study NCT04634682 by Myogem concluded. The study...